SILO
SiloFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
The supported bull case is narrow: SILO still has a defined lead asset path, and the latest 10-K indicates enough cash for at least twelve months from March 27, 2026 while SPC-15 advances toward a possible 2026 IND filing [#10-K-2026-03-27].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Clinical and regulatory timing risk around SPC-15, including whether IND-enabling work converts into an actual 2026 IND filing.
Momentum
47
Value
42
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.42 · Bull $0.55 · Bear $0.24
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Why
Momentum47 · Δ7d -
Value42 · Δ7d +0.0
Sentiment0 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
47
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 46.6 / Value 41.9 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$85.42M
Beta
0.60
Shares Out
13.32M
P/E (TTM) · Derived
-5.4
P/S (TTM)
65.38
P/FCF (TTM) · Derived
-8.22
Rev YoY
0.0%
EPS YoY
+44.9%
Gross Margin
+65.2%
Op Margin
-7359.2%
Net Debt
-$7.08M
Current Ratio
8.70
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology